ADAM8 inhibitors (Medivir)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameADAM8 inhibitors (Medivir)
Drug Alias NameADAM8 inhibitors (Cancer Research UK/King's College London)disintegrin and metalloproteinase domain-containing protein 8 inhibitor (Cancer Research UK/King's College London)BK-1361
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionADAM Metallopeptidase Domain 8 inhibitors
TargetsADAM Metallopeptidase Domain 8
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKing'S College London
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCancer Research TechnologyMedivir ABKing'S College London +[4] 
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A